pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

ifm-therapeutics PRESS RELEASE ARCHIVE

Dec 1, 2021

IFM Therapeutics Announces Extension of Collaboration Agreement for cGAS-STING Subsidiary, IFM Due

Jan 7, 2020

IFM Therapeutics Appoints Michael Cooke, Ph.D., as Chief Scientific Officer

Dec 2, 2019

IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer

Sep 5, 2019

IFM Therapeutics Announces Collaboration and Exclusive Option Agreement for cGAS/STING-Focused Subsidiary, IFM Due

May 8, 2019

IFM Therapeutics and Novartis Complete Previously Announced Acquisition of IFM Tre

Apr 1, 2019

Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System

Mar 28, 2019

IFM Therapeutics Announces Dosing of First Subjects in Phase 1 Healthy Volunteer Study of Lead NLRP3 Antagonist, IFM-2427

Feb 11, 2019

IFM Therapeutics, LLC Launches New Subsidiary, IFM Due, to Advance cGAS/STING Antagonists for Serious Inflammatory and Autoimmune Diseases

Dec 18, 2018

IFM Therapeutics Announces Newly Discovered Mechanism of Inflammatory Processes in the Body

Sep 13, 2018

IFM Therapeutics, LLC Appoints John Leonard, M.D. to Board of Directors

Aug 20, 2018

IFM Therapeutics, LLC Presents Promising Preclinical Data for NLRP3 Inhibitors at ACS 2018

Jul 30, 2018

IFM Therapeutics Announces New Publication in Nature Reviews Drug Discovery Examining NLRP3 as a Target in Serious Inflammatory and Immune-Mediated Diseases

Jul 19, 2018

IFM Therapeutics, LLC Launches Subsidiary, IFM Tre, with $31 Million Series A Financing to Develop NLRP3 Antagonists for Inflammatory Diseases

Jun 20, 2018

IFM Therapeutics, LLC Appoints World-Renowned Physicians and Researchers to Clinical Advisory Board

Mar 7, 2018

IFM Therapeutics and Bristol-Myers Squibb Awarded 2017 Deal of the Year by Clarivate Analytics

Dec 20, 2017

IFM Therapeutics LLC Appoints Dr. Michael Heneka to Clinical Advisory Board USA - English France - Français France - Français Deutschland - Deutsch Deutschland - Deutsch

Oct 5, 2017

IFM Therapeutics LLC Appoints William R. Roush as Executive Vice President of Chemistry

Aug 10, 2017

Regen BioPharma, Inc. Addresses Potential Impact of Recent Bristol Myers Squibb's $2.3 Billion Acquisition of IFM Therapeutics

Aug 9, 2017

Regen BioPharma, Inc. Addresses Potential Impact of Recent Bristol Myers Squibb $2.3 Billion Acquisition of IFM Therapeutics

Aug 3, 2017

Bristol-Myers Squibb to Acquire IFM Therapeutics to Strengthen Oncology Pipeline Focus on Innate Immunity

Aug 3, 2017

Bristol-Myers Squibb to Acquire IFM Therapeutics to Strengthen Oncology Pipeline Focus on Innate Immunity

May 23, 2017

IFM Therapeutics Appoints H. Martin Seidel as Executive Vice President of Research and Development

Feb 23, 2017

IFM Therapeutics Appoints Renowned Physicians from Academia and Industry to Clinical Advisory Board

Oct 26, 2016

IFM Therapeutics Establishes German Subsidiary and Research Site

Sep 6, 2016

IFM Therapeutics Appoints Leading Oncology, Immunology, and Chemistry Experts to Founding Scientific Advisory Board

Jun 22, 2016

IFM Therapeutics Raises $27 Million Series A Financing Led by Atlas Venture and Abingworth

Google Analytics Alternative